Literature DB >> 1632655

Inhibition of human serine proteases by substituted 2-azetidinones.

W B Knight1, R Chabin, B Green.   

Abstract

trans-4-Ethoxycarbonyl-3-ethyl-1-(4-nitrophenyl-sulfonyl)-azetidin -3-one described by Firestone et al. (1990, Tetrahedron 46, 2255) as an inhibitor of human leucocyte elastase (HLE) displayed potent, time-dependent inhibition of both HLE and human cathepsin G (Cat-G). The cis-isomer was 7- and 180-fold less active, respectively. The mechanism likely involves opening of the beta-lactam ring by the active site serine to form an acyl-enzyme intermediate(s). This intermediate partitions with ratios of 4:1 between turnover of the inhibitor and formation of relatively stable enzyme-inhibitor complexes from both enzymes. The final HLE-inhibitor complex reactivated with a half-life of 48 h at 25 degrees C and was 16-fold more stable than the Cat-G-inhibitor complex. The stability of the acyl-enzymes supports a "double hit" chemical mechanism involving both serine acylation and alkylation of the histidine. These observations suggest that beta-lactams may be developed as a class of serine protease inhibitors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1632655     DOI: 10.1016/0003-9861(92)90630-f

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  2 in total

1.  'pH-jump' crystallographic analyses of gamma-lactam-porcine pancreatic elastase complexes.

Authors:  P A Wright; R C Wilmouth; I J Clifton; C J Schofield
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

2.  Chemical, biochemical, pharmacokinetic, and biological properties of L-680,833: a potent, orally active monocyclic beta-lactam inhibitor of human polymorphonuclear leukocyte elastase.

Authors:  J B Doherty; S K Shah; P E Finke; C P Dorn; W K Hagmann; J J Hale; A L Kissinger; K R Thompson; K Brause; G O Chandler
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.